|
|
||||||||||||||
|
|
|||||||||||||||
a Center for Dystonia, Neurological Institute,
Columbia-Presbyterian Medical Center, b Sergievsky Center, Columbia
University, New York, USA
Correspondence to: Dr Blair Ford, Neurological Institute, Columbia College of Physicians, 710 West 168th Street, New York 10032, USA. Telephone 001 212 305 5548; fax 001 212 305 1304; email Ford{at}movdis.cis.columbia.edu
Received 18
December 1997 and in revised form 11 March 1998;
Accepted 19 March 1998
OBJECTIVE
To investigate the long term outcome of
selective ramisectomy denervation in patients with botulinum toxin
resistant spasmodic torticollis.
BACKGROUND
The published surgical series of
ramisectomy treatment for torticollis do not provide systematic
information on patients who develop resistance to the current standard
of treatment
botulium toxin injections. Moreover, there is little
information on surgical outcome using rating scale measurements of
torticollis, or assessments of functional and occupational capacity.
METHODS
Using a structured interview format and
videotape assessments of severity of dystonia in a retrospective
fashion, detailed follow up information was obtained on 16 patients who
underwent open label selective denervation for severe, disabling
torticollis, refractory to injections of botulinum toxin.
RESULTS
Of 16 patients with disabling torticollis
followed up postoperatively for a mean of 5 years, six (37.5%) had a
moderate or complete return of normal neck function, as determined
using functional capacity scales, whereas 10 had only minimal relief of
dystonia or gain in function. Six of the 16 patients (37.5%) underwent a second peripheral denervation operation, and one required a third. Of
11 patients working outside the home before surgery, nine were disabled
by dystonia, and only one continued to work after surgery. Dystonia
rating scale scores of videotaped examinations using a modification of
the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)
improved in 12 of 14 patients (85.7%) who underwent selective
ramisectomy. When patients with primary botulinum toxin resistance were
excluded, the magnitude of benefit for this subgroup was 31.9% of the
baseline dystonia score (p<0.0002), comparable with the degree of
improvement in a group of control patients receiving botulinum toxin
treatment for torticollis.
CONCLUSION
About one third of patients with
torticollis resistant to injections of botulinum toxin may derive
modest long term functional improvement from selective denervation,
with a reduction in dystonia by about 30%, but remain unable to work.
This article has been cited by other articles:
![]() |
K. Dashtipour, M. Barahimi, and S. Karkar Cervical Dystonia Journal of Pharmacy Practice, December 1, 2007; 20(6): 449 - 457. [Abstract] [PDF] |
||||
![]() |
J K Krauss, T J Loher, T Pohle, S Weber, E Taub, C B Barlocher, and J-M Burgunder Pallidal deep brain stimulation in patients with cervical dystonia and severe cervical dyskinesias with cervical myelopathy J. Neurol. Neurosurg. Psychiatry, February 1, 2002; 72(2): 249 - 256. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Andaluz, J. M. Taha, and A. Dalvi Bilateral pallidal deep brain stimulation for cervical and truncal dystonia Neurology, August 14, 2001; 57(3): 557 - 558. [Full Text] [PDF] |
||||
![]() |
A Munchau, C D Good, S McGowan, N P Quinn, J D Palmer, and K P Bhatia Prospective study of swallowing function in patients with cervical dystonia undergoing selective peripheral denervation J. Neurol. Neurosurg. Psychiatry, July 1, 2001; 71(1): 67 - 72. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Munchau, J. D. Palmer, D. Dressler, J. D. O'Sullivan, K. L. Tsang, M. Jahanshahi, N. P. Quinn, A. J. Lees, and K. P. Bhatia Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia Brain, April 1, 2001; 124(4): 769 - 783. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |